Inborn errors of metabolism have wide and profound effects in many or all organs, and especially so in those with endocrine functions. The testes are greatly affected by systemic metabolic disorders, leading to specific histological findings that generally reveal the nature of the underlying disorder. Here we describe the main testicular changes seen in the setting of metabolic disease.
VantyghemMC, DobbelaereD, MentionK, WemeauJL, SaudubrayJM, DouillardC. Endocrine manifestations related to inherited metabolic diseases in adults. Orphanet J Rare Dis2012;7:11.
2.
McLarenCE, GordeukVR, LookerACPrevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood1995;86:2021–2027.
3.
BradleyLA, HaddowJE, PalomakiGE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen1996;3:178–184.
4.
EdwardsCQ, GriffenLM, GoldgarD, DrummondC, SkolnickMH, KushnerJP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med1988;318:1355–1362.
5.
McDonnellSM, WitteDL, CogswellME, McIntyreR. Strategies to increase detection of hemochromatosis. Ann Intern Med1998;129:987–992.
6.
NiederauC, NiederauCM, LangeSScreening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med1998;128:337–345.
7.
PressRD. Hereditary hemochromatosis: impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease. Arch Pathol Lab Med1999;123:1053–1059.
8.
FederJN, GnirkeA, ThomasWA novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet1996;13:399–408.
9.
NjajouOT, VaessenN, JoosseMA mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet2001;28:213–214.
RoettoA, TotaroA, PipernoANew mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood2001;97:2555–2560.
12.
JazwinskaEC, CullenLM, BusfieldFHaemochromatosis and HLA-H. Nat Genet1996;14:249–251.
13.
SantosPC, CancadoRD, PereiraAC, ChiattoneCS, KriegerJE, Guerra-ShinoharaEM. HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox. Acta Haematol2010;124:204–205.
14.
BridleKR, FrazerDM, WilkinsSJDisrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet2003;361:669–673.
RivardSR, MuraC, SimardHClinical and molecular aspects of juvenile hemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Blood Cells Mol Dis2000;26:10–14.
17.
MilitaruMS, PoppRA, TrifaAP. Homozygous G320V mutation in the HJV gene causing juvenile hereditary haemochromatosis type A. A case report. J Gastrointestin Liver Dis2010;19:191–193.
18.
BerentR, AllingerS, HoblingW, AuerJ, KnoflachP. A 24-year-old patient with decreased libido and erectile dysfunction as initial manifestations of hemochromatosis [in German]. Dtsch Med Wochenschr2000;125:1466–1468.
McDermottJH, WalshCH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab2005;90:2451–2455.
21.
KontogeorgosG, HandyS, KovacsK, HorvathE, ScheithauerBW. The anterior pituitary in hemochromatosis. Endocr Pathol1996;7:159–164.
22.
AngelopoulosNG, GoulaA, DimitriouE, TolisG. Reversibility of hypogonadotropic hypogonadism in a patient with the juvenile form of hemochromatosis. Fertil Steril2005;84:1744.
23.
GamaR, SmithMJ, WrightJ, MarksV. Hypopituitarism in primary haemochromatosis; recovery after iron depletion. Postgrad Med J1995;71:297–298.
24.
HamerOW, GnadM, ScholmerichJ, PalitzschKD. Successful treatment of erectile dysfunction and infertility by venesection in a patient with primary haemochromatosis. Eur J Gastroenterol Hepatol2001;13:985–988.
25.
NiederauC. Hereditary hemochromatosis [in German]. Med Klin (Munich). 2009;104:931–946.
26.
MadersbacherS, GrunbergerT, MaierU. Andrological status before and after liver transplantation. J Urol1994;151:1251–1254.
27.
OehningerS, PikeI, SlotnickN. Hemochromatosis and male infertility. Obstet Gynecol1998;92 (4, pt 2):652–653.
28.
NiederauC, StremmelW, StrohmeyerGW. Clinical spectrum and management of haemochromatosis. Baillieres Clin Haematol1994;7:881–901.
29.
StopforthHB, HeynsCF, De KockML, SandlerM. Ejaculatory failure and hypogonadotrophic hypogonadism caused by haemochromatosis. BJU Int1999;83:728.
30.
KaufmanFR, KogutMD, DonnellGN, GoebelsmannU, MarchC, KochR. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med1981;304:994–998.
31.
Rubio-GozalboME, PanisB, ZimmermannLJ, SpaapenLJ, MenheerePP. The endocrine system in treated patients with classical galactosemia. Mol Genet Metab2006;89:316–322.
32.
SchweitzerS, ShinY, JakobsC, BrodehlJ. Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr1993;152:36–43.
33.
GubbelsCS, WeltCK, DumoulinJCThe male reproductive system in classic galactosemia: cryptorchidism and low semen volume. J Inherit Metab Dis2013;36:779–786.
34.
KearnsTP, SayreGP. Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol1958;60:280–289.
35.
HarveyJN, BarnettD. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf)1992;37:97–103.
36.
FilhoLA Zago, ShiokawaN. Kearns-Sayre syndrome: two case reports [in Portuguese]. Arquivos brasileiros de oftalmologia.2009;72:95–98.
37.
Carod-ArtalFJ, GallardoE Lopez, SolanoA, DahmaniY, HerreroMD, MontoyaJ. Mitochondrial DNA deletions in Kearns-Sayre syndrome [in Spanish]. Neurologia.2006;21:357–364.
38.
JohnsDR. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med1995;333:638–644.
39.
McDonaldDG, McMenaminJB, FarrellMA, DrooganO, GreenAJ. Familial childhood onset neuropathy and cirrhosis with the 4977bp mitochondrial DNA deletion. Am J Med Genet2002;111:191–194.
40.
BolesRG, RoeT, SenadheeraD, MahnovskiV, WongLJ. Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease. Eur J Pediatr1998;157:643–647.
41.
ComteC, ToninY, Heckel-MagerAMMitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre syndrome. Nucleic Acids Res2013;41:418–433.
42.
HomanDJ, NiyazovDM, FisherPWHeart transplantation for a patient with Kearns-Sayre syndrome and end-stage heart failure. Congest Heart Fail2011;17:102–104.
43.
PhadkeM, LokeshwarMR, BhutadaSKearns Sayre Syndrome—case report with review of literature. Indian J Pediatr2012;79:650–654.
44.
BraunA, AmbachH, KammererSMutations in the gene for X-linked adrenoleukodystrophy in patients with different clinical phenotypes. Am J Hum Genet1995;56:854–861.
45.
GrahamGE, MacLeodPM, LillicrapDP, BridgePJ. Gonadal mosaicism in a family with adrenoleukodystrophy: molecular diagnosis of carrier status among daughters of a gonadal mosaic when direct detection of the mutation is not possible. J Inherit Metab Dis1992;15:68–74.
46.
LauretiS, CasucciG, SanteusanioF, AngelettiG, AubourgP, BrunettiP. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab1996;81:470–474.
47.
LazoO, ContrerasM, HashmiM, StanleyW, IrazuC, SinghI. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA1988;85:7647–7651.
48.
PaikMJ, KimKR, YoonHR, KimHJ. Diagnostic patterns of very-long-chain fatty acids in plasma of patients with X-linked adrenoleukodystrophy. J Chromatogr B Biomed Sci Appl2001;760:149–157.
49.
MoserHW, RaymondGV, DubeyP. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA2005;294:3131–3134.
50.
BezmanL, MoserAB, RaymondGVAdrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol2001;49:512–517.
51.
TakemotoY, SuzukiY, TamakoshiAEpidemiology of X-linked adrenoleukodystrophy in Japan. J Hum Genet2002;47:590–593.
van RoermundCW, VisserWF, IjlstLThe human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J2008;22:4201–4208.
54.
X-linked Adrenoleukodystrophy Database [database online]. 2013. Available at http://www.x-ald.nl. Accessed January 2016.
55.
MoserHW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain1997;120 (pt 8):1485–1508.
56.
FarrellDF. Neonatal adrenoleukodystrophy: a clinical, pathologic, and biochemical study. Pediatr Neurol2012;47:330–336.
57.
GulerAS, FisNP, BerkemM. X-linked adrenoleukodystrophy in a 7-year-old boy presenting with psychiatric symptoms. Eur Child Adolesc Psychiatry2011;20:275–276.
JiaZ, PeiZ, LiY, WeiL, SmithKD, WatkinsPA. X-linked adrenoleukodystrophy: role of very long-chain acyl-CoA synthetases. Mol Genet Metab2004;83:117–127.
60.
MoserHW, SmithKD, MoserAB. X-linked adrenoleukodystrophy. In: ScriverCR, BeandetAL, SlyWS, ValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995:3325–3344.
61.
RaiPV Santosh, SureshBV, BhatIG, SekharM, ChakrabortiS.Childhood adrenoleukodystrophy—classic and variant—review of clinical manifestations and magnetic resonance imaging. J Pediatr Neurosci2013;8:192–197.
62.
HubbardWC, MoserAB, LiuACNewborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab2009;97:212–220.
63.
SuzukiY, TakemotoY, ShimozawaNNatural history of X-linked adrenoleukodystrophy in Japan. Brain Dev2005;27:353–357.
64.
MoserHW, MoserAB, NaiduS, BerginA. Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci1991;13:254–261.
65.
AssiesJ, GoorenLJ, Van GeelB, BarthPG. Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. Int J Androl1997;20:315–321.
PowersJM, SchaumburgHH. The testis in adrenoleukodystrophy. Am J Pathol1981;102:90–98.
68.
AversaA, PalleschiS, CruccuG, SilvestroniL, IsidoriA, FabbriA. Rapid decline of fertility in a case of adrenoleukodystrophy. Hum Reprod1998;13:2474–2479.
LibberSM, MigeonCJ, BrownFR3rd, MoserHW. Adrenal and testicular function in 14 patients with adrenoleukodystrophy or adrenomyeloneuropathy. Horm Res1986;24:1–8.
PoticA, RovelliAM, UzielG, KozicD, MladenovicJ, Milic-RasicV. Childhood cerebral X-linked adrenoleukodystrophy more than 5 years after hematopoietic cell transplantation: the first case from Serbia and southeastern Europe. J Child Neurol2010;25:1542–1547.
73.
FabryJ. Ein Beitrag zur kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemoffhagic hebrae). Arch Dermatol Syph1898;43:187–200.
74.
AndersonWA. A case of angiokeratoma. Br J Dermatol1898;18:113–117.
75.
MeiklePJ, HopwoodJJ, ClagueAE, CareyWF. Prevalence of lysosomal storage disorders. JAMA1999;281:249–254.
76.
SpadaM, PagliardiniS, YasudaMHigh incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet2006;79:31–40.
77.
AltarescuGM, GoldfarbLG, ParkKYIdentification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet2001;60:46–51.
78.
AshleyGA, ShabbeerJ, YasudaM, EngCM, DesnickRJ. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J Hum Genet2001;46:192–196.
79.
YangCC, LaiLW, WhitehairO, HwuWL, ChiangSC, LienYH. Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease. Clin Genet2003;63:205–209.
80.
FaggianoA, PisaniA, MiloneFEndocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab2006;91:4319–4325.
81.
RiesM, RamaswamiU, PariniRThe early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr2003;162:767–772.
82.
BradyRO, SchiffmannR.Clinical features of and recent advances in therapy for Fabry disease. JAMA2000;284:2771–2775.
83.
LacombeD, GermainDP, Papaxanthos-Roche A. Azoospermia as a new feature of Fabry disease [in French]. Rev Med Interne2010;31 (suppl 2):S214–S216.
84.
NistalM, PaniaguaR, PicazoML. Testicular and epididymal involvement in Fabry's disease. J Pathol1983;141:113–124.
85.
ThurbergBL, PoliteiJM. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. Hum Pathol2012;43:610–614.
86.
DesnickRJ, BradyR, BarrangerJFabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med2003;138:338–346.
87.
EngCM, GuffonN, WilcoxWRSafety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N Engl J Med2001;345:9–16.
88.
RamaswamiU. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther2011;5:155–173.
89.
RiesM, ClarkeJT, WhybraCEnzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics2006;118:924–932.
90.
SchwartingA, DehoutF, FeriozziS, BeckM, MehtaA, Sunder-PlassmannG. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol2006;66:77–84.
91.
AndersonRA, RaoN, ByrumRSIn situ localization of the genetic locus encoding the lysosomal acid lipase/cholesteryl esterase (LIPA) deficient in Wolman disease to chromosome 10q23.2-q23.3. Genomics1993;15:245–247.
92.
LajoA, GraciaR, NavarroM, NistalM, RabadanB. Wolman's disease. Acute infantile form [in Spanish]. An Esp Pediatr1974;7:438–446.
93.
ContrerasF, AlvarezL, NistalM, ClaverM. Enfermedad de Wolman. Estudio anatomopatológico de dos observaciones. Patología1974;7:189–200.
94.
AssmannG, SeedorfU. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: ScriverCR, BeaudetAI, SlyWS, ValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001;3551–3572.
95.
RassoulF, RichterV, LohseP, NaumannA, PurschwitzK, KellerE. Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease. Int J Clin Pharmacol Ther2001;39:199–204.
96.
CoatesPM, CortnerJA, HoffmanGM, BrownSA. Acid lipase activity of human lymphocytes. Biochim Biophys Acta1979;572:225–234.
97.
DairakuT, IwamotoT, NishimuraM, EndoM, OhashiT, EtoY. A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease. Mol Genet Metab2014;111:193–196.
98.
HamiltonJ, JonesI, SrivastavaR, GallowayP. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta2012;413:1207–1210.
99.
CivalleroG, De MariJ, BittarC, BurinM, GiuglianiR. Extended use of a selective inhibitor of acid lipase for the diagnosis of Wolman disease and cholesteryl ester storage disease. Gene2014;539:154–156.
100.
SunXR, RisbridgerGP. Site of macrophage inhibition of luteinizing hormone-stimulated testosterone production by purified leydig cells. Biol Reprod1994;50:363–367.
101.
EllederM, ChlumskaA, LedvinovaJ, PoupetovaH. Testis—a novel storage site in human cholesteryl ester storage disease. Autopsy report of an adult case with a long-standing subclinical course complicated by accelerated atherosclerosis and liver carcinoma. Virchows Arch2000;436:82–87.
102.
GramatgesMM, DvorakCC, RegulaDP, EnnsGM, WeinbergK, AgarwalR. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant2009;44:449–450.
103.
SteinJ, GartyBZ, DrorY, FenigE, ZeiglerM, YanivI. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr2007;166:663–666.
104.
TolarJ, PetrykA, KhanKLong-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant2009;43:21–27.
105.
ReynoldsT. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. J Clin Pathol2013;66:918–923.
106.
CrockerAC, FarberS. Niemann-Pick disease: a review of eighteen patients. Medicine (Baltimore)1958;37:1–95.
LiscumL, SturleySL. Intracellular trafficking of Niemann-Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim Biophys Acta2004;1685:22–27.
109.
VanierMT, SuzukiK. Recent advances in elucidating Niemann-Pick C disease. Brain Pathol1998;8:163–174.
110.
CarsteaED, MorrisJA, ColemanKGNiemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science1997;277:228–231.
111.
NaureckieneS, SleatDE, LacklandHIdentification of HE1 as the second gene of Niemann-Pick C disease. Science2000;290:2298–2301.
112.
WangC, MaZ, ScottMP, HuangX. The cholesterol trafficking protein NPC1 is required for Drosophila spermatogenesis. Dev Biol2011;351:146–155.
113.
ButlerA, HeX, GordonRE, WuHS, GattS, SchuchmanEH. Reproductive pathology and sperm physiology in acid sphingomyelinase-deficient mice. Am J Pathol2002;161:1061–1075.
114.
FanJ, AkabaneH, GrahamSN, RichardsonLL, ZhuGZ. Sperm defects in mice lacking a functional Niemann-Pick C1 protein. Mol Reprod Dev2006;73:1284–1291.
115.
SachsB. On arrested cerebral development with special reference to its cortical pathology. J Nerv Ment Dis1887;14:541–553.
116.
KrishnamoorthyKS, EichlerF, RapalinoO, FroschMP. Case records of the Massachusetts General Hospital. Case 14-2014. An 11-month-old girl with developmental delay. N Engl J Med2014;370:1830–1841.
TraslerJ, SaberiF, SomaniIHCharacterization of the testis and epididymis in mouse models of human Tay Sachs and Sandhoff diseases and partial determination of accumulated gangliosides. Endocrinology1998;139:3280–3288.
119.
McDowellG, IsogaiT, TanigamiAFine mapping of the cystinosis gene using an integrated genetic and physical map of a region within human chromosome band 17p13. Biochem Mol Med1996;58:135–141.
120.
TouchmanJW, AniksterY, DietrichNLThe genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res2000;10:165–173.
121.
BroyerM. Cystinosis from childhood to adulthood [in French]. Nephrologie2000;21:13–18.
122.
WinklerL, OffnerG, KrullF, BrodehlJ. Growth and pubertal development in nephropathic cystinosis. Eur J Pediatr1993;152:244–249.
123.
BesouwMT, KremerJA, JanssenMC, LevtchenkoEN. Fertility status in male cystinosis patients treated with cysteamine. Fertil Steril2010;93:1880–1883.
124.
ChikCL, FriedmanA, MerriamGR, GahlWA. Pituitary-testicular function in nephropathic cystinosis. Ann Intern Med1993;119 (7, pt 1):568–575.
125.
HillenbrandM, StropahlG, SeiterH. Massive tumour-like testicular cystine accumulation in a patient with infantile nephropathic cystinosis. Br J Urol1998;81:331–332.
126.
TegtmeyerLC, RustS, van ScherpenzeelMMultiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med2014;370:533–542.
127.
MizugishiK, YamanakaK, KuwajimaK, YuasaI, ShigemotoK, KondoI. Missense mutations in the phosphomannomutase 2 gene of two Japanese siblings with carbohydrate-deficient glycoprotein syndrome type I. Brain Dev1999;21:223–228.
128.
KrasnewichD, O'BrienK, SparksS. Clinical features in adults with congenital disorders of glycosylation type Ia (CDG-Ia). Am J Med Genet C Semin Med Genet2007;145C:302–306.
129.
AlströmCH, HallgrenB, NilssonLB, AsanderH. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree. Acta Psychiatr Neurol Scand Suppl1959;129:1–35.
130.
EdwardsJA, SethiPK, ScomaAJ, BannermanRM, FrohmanLA. A new familial syndrome characterized by pigmentary retinopathy, hypogonadism, mental retardation, nerve deafness and glucose intolerance. Am J Med1976;60:23–32.
131.
KleinD. Diverse clinical and genetic varieties of the Bardet-Biedl syndrome [in French]. Rev Otoneuroophtalmol1968;40:125–144.
132.
KocE, BayrakG, SuherM, EnsariC, AktasD, EnsariA. Rare case of Alstrom syndrome without obesity and with short stature, diagnosed in adulthood. Nephrology. 2006;11:81–84.
133.
CollinGB, MarshallJD, CardonLR, NishinaPM. Homozygosity mapping at Alstrom syndrome to chromosome 2p. Hum Mol Genet1997;6:213–219.
134.
CollinGB, MarshallJD, IkedaAMutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet2002;31:74–78.
KatagiriS, YoshitakeK, AkahoriMWhole-exome sequencing identifies a novel ALMS1 mutation (p.Q2051X) in two Japanese brothers with Alstrom syndrome. Mol Vis2013;19:2393–2406.
Russell-EggittIM, ClaytonPT, CoffeyR, KrissA, TaylorDS, TaylorJF. Alstrom syndrome. Report of 22 cases and literature review. Ophthalmology1998;105:1274–1280.
139.
HearnT, SpallutoC, PhillipsVJSubcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes2005;54:1581–1587.
140.
AdamsM, SmithUM, LoganCV, JohnsonCA. Recent advances in the molecular pathology, cell biology and genetics of ciliopathies. J Med Genet2008;45:257–267.
141.
MintonJA, OwenKR, RickettsCJSyndromic obesity and diabetes: changes in body composition with age and mutation analysis of ALMS1 in 12 United Kingdom kindreds with Alstrom syndrome. J Clin Endocrinol Metab2006;91:3110–3116.
142.
KuburovicV, MarshallJD, CollinGBDifferences in the clinical spectrum of two adolescent male patients with Alstrom syndrome. Clin Dysmorphol2013;22:7–12.
143.
MarshallJD, BronsonRT, CollinGBNew Alstrom syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med2005;165:675–683.
144.
EvansPM, AnsariBM, PageMD. Alstrom's syndrome with Kleinfelter's karyotype. J Int Med2000;248:89–92.
145.
DumitrescuAM, RefetoffS. Inherited defects of thyroid hormone metabolism. Ann Endocrinol (Paris)2011;72:95–98.
146.
SchoenmakersE, AgostiniM, MitchellCMutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest2010;120:4220–4235.
